Diabetes company to cut 200 jobs

Pharmaceutical company Amylin Pharmaceuticals, who sell diabetes drug Byetta, are going to let around 200 jobs go. The redundancies comprise approximately a third of the sales force of the company .
Alongside Eli Lilly, Amylin are developing a once-per-week version of diabetes drug Byetta. The aim of the restructuring is to strengthen the sales efficiency and the partnership with Lilly.
Amylin are thought to be seeking a final sales team of 325 representatives. The team will focus on doctors and endocrinologists who treat large number of people with diabetes .
The diabetes company, who largely specialise in drug for people with type 2 diabetes, will aim to save millions through the changes in the next few years.